Cell mediated immunity to meet the avian influenza A (H5N1) challenge

Medical Hypotheses

Volumn 67, Issue 3, 2006, Pages 601-608

  Pizza, Giancarlo ^a   Amadori, Massimo ^b   Ablashi, Dharam ^c   De Vinci, Caterina ^a   Viza, Dimitri ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

^c The HHV 6 Foundation   (United States)

^d BioTransfer Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; TRANSFER FACTOR;

ALLERGY; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AVIAN INFLUENZA; AVIAN INFLUENZA A SUBTYPE H5N1; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG INDICATION; DRUG POTENCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS; MULTIPLE SCLEROSIS; MYCOSIS; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION REACTION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS VIRULENCE;

ANIMALS; BIRDS; DISEASE OUTBREAKS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MODELS, IMMUNOLOGICAL;

AVES; HUMAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 33745260686     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.02.034     Document Type: Article

References (74)

1. Avian influenza A (H5N1). Weekly Epidemiol Rec 2004;79(7):65-70.
2. Nguyen D.C., Uyeki T.M., Jadhao S., et al. Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol 79 7 (2005) 4201-4212
3. Keawcharoen J., Oraveerakul K., Kuiken T., et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 10 12 (2004) 2189-2191
4. Thanawongnuwech R., Amonsin A., Tantilertcharoen R., et al. Probable tiger-to-tiger transmission of avian influenza H5N1. Emerg Infect Dis 11 5 (2005) 699-701
5. Choi Y.K., Nguyen T.D., Ozaki H., et al. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand. J Virol 79 16 (2005) 10821-10825
6. Zitzow L.A., Rowe T., Morken T., et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76 9 (2002) 4420-4429
7. Govorkova E.A., Rehg J.E., Krauss S., et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79 4 (2005) 2191-2198
8. Maines T.R., Lu X.H., Erb S.M., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
9. Jeter W.S., Tremaine M., and Seeborn P. Passive transfer of delayed hypersensitivity to 2,4-dinitrochlorobenzene in guinea pigs with leucocytic extracts. Proc Soc Exp Biol Med 86 (1954) 251-259
10. Lawrence H.S. The transfer of generalized cutaneous hypersensitivity of the delayed tuberculin type in man by means of the constituents of disrupted leucocytes. J Clin Inv 33 6 (1954) 951-952
11. Lawrence H.S. The transfer in humans of delayed skin sensitivity to streptococci M substance and to tuberculin with disrupted leukocytes. J Clin Inv 34 (1955) 219-232
12. Viza D., Goust J.M., Moulias R., et al. Invitro production of transfer factor by lymphoblastoid cell lines. Transplant VII Suppl. 1 (1975) 329-333
13. Viza D., Boucheix C., Césarini J.P., Ablashi D.V., Armstrong G., Levine P.H., et al. Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Biol Cell 46 (1982) 1-10
14. Boucheix C., Phillips J., Pizza G., Sartorio C., and Viza D. Activity of animal transfer factor in man. Lancet i (1977) 189-199
15. Vich J.M., Garcia J.V., Engel P., and Garcia P.A. Transfer to man of sensitization to keyhole limpet haemocyanin by mouse transfer factor. Lancet i (1978) 265
16. Kirkpatrick C.H. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med 6 4 (2000) 332-341
17. Viza D. AIDS and transfer factor: myths, certainties and realities. Biotherapy 9 1-3 (1996) 17-26
18. Rappaport F.T., Lawrence H.S., Millar J.W., Pappagianis D., and Smith C.E. Transfer of delayed hypersensitivity to coccidioidin in man. J Immunol 84 (1960) 358-367
19. Burger D.R., Vandenbark A.A., Dunnic W., Kraybill W.G., and Vetto R.M. Properties of human transfer factor from KLH-immunized donors: Dissociation of dermal transfer and proliferation augmenting activities. J Retic Soc 24 (1976) 385-402
20. Lawrence H.S., and Borkowsky W. Transfer factor - Current status and future prospects. Biotherapy 9 1-3 (1996) 1-5
21. Fudenberg H.H., Levin A.S., Spitler L.E., Wybran J., and Byers V. The therapeutic uses of transfer factor. Hosp Pract 9 (1974) 95-104
22. Levin A.S., Byers V.S., Fudenberg H.H., et al. Osteogenic sarcoma - immunological parameters before and during immunotherapy with tumor-specific transfer-factor. J Clin Invest 55 3 (1975) 487-499
23. Fudenberg H.H. Dialyzable transfer-factor in treatment of human osteosarcoma - analytic review. Ann NY Acad Sci 277 (1976) 545-557
24. Neequaye J., Viza D., Pizza G., et al. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticanc Res 10 (1990) 1183-1187
25. Prasad U., bin Jalaludin M.A., Rajadurai P., et al. Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 9 (1996) 109-115
26. Pizza G., De Vinci C., Lo Conte G., Capanna R., et al. Immunotherapy of metastatic kidney cancer. Int J Canc 94 (2001) 109-120
27. Pizza G., De Vinci C., and Viza D. Immunotherapeutic approaches for renal cancer. Fol Biol 48 (2002) 167-181
28. Sharma M.K., Anaraki F., and Ala F. Preliminary results of transfer factor therapy of persistent cutaneous leishmania infection. Clin Immunol Immunopathol 12 (1979) 183-190
29. Sharma M., Firouz R., and Ala F. Transfer factor therapy in human cutaneous leishmania infection (CLI): A double-blind clinical trial in immune regulators. In: Khan A., Kirkpatrick C.H., and Hill N.O. (Eds). Transfer factor (1979), Academic Press, NY 563-570
30. Delgado O., Romano E.L., Belfort E., Pifano F., Scorza J.V., and Rojas Z. Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunopathol 19 (1981) 351-358
31. McMeeking A., Borkowski W., Klesius P.H., et al. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infec Dis 161 (1990) 108-112
32. Spitler L.E., Levin A.S., Stites D.P., et al. The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest 51 (1972) 3216-3224
33. Griscelli C., Revillard J.P., Betuel H., Herzog C., and Touraine J.L. Transfer factor therapy in immunodeficiencies. Biomed 18 (1973) 220-227
34. Galbraith G.M.P., and Fudenberg H.H. Transfer factor. In: Stone J. (Ed). Dermatologic Immunology and Allergy (1985), Mosby, St. Louis, MO 889-898
35. Fudenberg H.H., and Fudenberg H.L. Transfer factor: past, present and future. In: Jucker E. (Ed). Annual review of pharmacology and toxicology (1989), Birkhäuser Verlag, Basel, Switzerland 475-516
36. Nkrumah F., Pizza G., Viza D., et al. Regression of progressive lymphadenopathy in a young child with acute CMV infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 4 (1985) 237-241
37. Ablashi D.V., Levine P.H., De Vinci C., et al. Use of anti HHV-6 transfer factor for the treatment of two patients with Chronic Fatigue Syndrome (CFS). Two case reports. Biotherapy 9 (1996) 81-86
38. Steele W.R., Myers M.G., and Vincent M.M. Transfer factor for the prevention of varicella zoster infection in childhood leukaemia. N Eng J Med 303 (1980) 355-359
39. Steele W.R. Transfer factor and cellular reactivity to varicella zoster antigen in childhood leukaemia. Cell Immun 50 (1980) 202-289
40. Dwyer J.M. The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: Kirkpatrick C.H., et al. (Ed). Immunobiology of transfer factor (1983), Academic Press, New York 233-243
41. Rosenfeld F., Viza D., Phillips J., Vich J.M., Binet O., and Aron-Brunctière R. Traitement des infections herpétiques par le facteur de transfert. Pres Méd 13 (1984) 537-540
42. Viza D., Vich J.M., Phillips J., and Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 4 (1985) 27-30
43. Viza D., Vich J.M., Phillips J., and Davies D.A.L. Use of specific transfer factor for the prevention or the treatment of herpes infections in mice and man. J Exp Pathol 3 (1987) 407-420
44. Pizza G., Meduri R., DeVinci C., et al. Transfer factor prevents relapses in herpes keratitis patients: A pilot study. Biotherapy 8 (1995) 63-68
45. Meduri R., Campos E., Scorolli L., et al. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 9 (1996) 61-66
46. Viza D., Vich J.M., Phillips J., Rosenfeld F., and Davies D.A.L. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immunol 100 (1986) 555-562
47. Steele R.W., Heberling R.L., Eichberg J.W., et al. Prevention of herpes simplex virus type 1 fatal dissemination in primates with human transfer factor. In: Ascher M.S., Gottlieb A.A., and Kirkpatrick C.H. (Eds). Transfer factor. Basic properties and clinical applications (1976), Academic Press, New York 381-388
48. Viza D., Vich J.M., Minarro A., and Ablashi D.V. Soluble extracts from a lymphoblastoid cell line modulate SAIDS evolution. J Virol Met 21 (1988) 241-253
49. Pizza G., Viza D., Roda A., et al. Transfer factor for the treatment of chronic active hepatitis. N Eng J Med 300 (1979) 1332
50. Roda E., Viza D., Pizza G., et al. Transfer-factor for the treatment of Hbsag-positive chronic active hepatitis. Proc Soc Exp Biol Med 178 3 (1985) 468-475
51. Vich J.M., and Viza D. Specific suppressor dialysates from mice. In: Kirkpatrick C.H., Burger D.R., and Lawrence H.S. (Eds). Immunobiology of transfer factor (1983), Academic Press, New York 197-202
52. Sims L.D., Domenech J., Benigno C., et al. Origin and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet Rec 157 6 (2005) 159-169
53. Chan M.C., Cheung C.Y., Chui W.H., et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6 1 (2005) 135-141
54. Ligon B.L. Avian influenza virus H5N1: A review of its history and information regarding its potential to cause the next pandemic. Semin Pediatr Infect Dis 16 4 (2005) 326-335
55. Van Borm S., Thomas I., Hanquet G., et al. Highly pathogenic H5N1 influenza virus in smuggled Thai eagles, Belgium. Emerg Infect Dis 11 5 (2005) 702-705
56. CBO: Flu pandemic could cause recession, Kill 2 Million. Dow Jones Newswires. December 8, 2005.
57. Olson G.B., and Drube C.G. Modulation of influenza in mice by transfer factor therapy. J Reticul Soc 24 5 (1978) 589-599
58. Stephenson I. Are we ready for pandemic influenza H5N1?. Expert Rev Vaccines 4 2 (2005) 151-155
59. Treanor J.J., Wilkinson B.E., Masseoud F., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732-1737
60. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
61. Stephenson I., Bugarini R., Nicholson K.G., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
62. Hoelscher M.A., Garg S., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 (2006) 475-481
63. Gao W., Soloff A.C., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80 4 (2006) 1959-1964
64. To K.F., Chan P.K., Chan K.F., et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 63 3 (2001) 242-246
65. Cheung C.Y., Poon L.L., Lau A.S., et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 360 9348 (2002) 1831-1837
66. Peiris J.S., Yu W.C., Leung C.W., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 9409 (2004) 617-619
67. WHO. The Writing Committee Consultation on Human Influenza A/H5: Avian influenza A (H5N1) infection in humans. N Engl J Med 353 (2005) 1374-1385
68. Raise E., Guerra L., Viza D., et al. Preliminary results in HIV-1-infected patients treated with Transfer Factor (TF) and Zidovudine (Zdv). Biotherapy 9 (1996) 49-54
69. Alvarezthull L., and Kirkpatrick C.H. Profiles of cytokine production in recipients of transfer factors. Biotherapy 9 1-3 (1996) 55-59
70. Ojeda O.M., Fernandez Ortega C.B., and Arana Rosainz M.J. Dialysable leucicyte extract (DLE) reduces liposacacharide-induced tumour necrosis factor secretion in human leucocytes. Biotherapy 9 (1996) 163-170
71. Guan Y., Peiris J.S., Lipatov A.S., et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci USA 99 13 (2002) 8950-8955
72. Horimoto T., Fukuda N., Iwatsuki-Horimoto K., et al. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 66 3 (2004) 303-305
73. Li K.S., Guan Y., Wang J., Smith G.J., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 6996 (2004) 209-213
74. Sims L.D., Ellis T.M., Liu K.K., et al. Avian influenza in Hong Kong 1997-2002. Avian Dis 47 Suppl. 3 (2003) 832-838